Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 1999 for Bioanalytical Systems, Inc. (Note: The request metadata lists "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.). The Company provides laboratory services, consulting, and research related to analytical chemistry, and manufactures scientific instruments for trace organic compound determination. Customers are located in the U.S. and internationally.
Key Financial Metrics
| Metric | Q1 FY2000 (Ended Dec 31, 1999) | Q1 FY1999 (Ended Dec 31, 1998) |
|---|---|---|
| Total Revenue | $4,446,000 | $4,598,000 |
| Gross Profit | $1,409,000 | $2,096,000 |
| Operating Income (Loss) | $(472,000) | $18,000 |
| Net Loss | $(372,000) | $(6,000) |
| Cash and Cash Equivalents (End of Period) | $597,000 | $437,000 |
| Net Cash Used in Operating Activities | $(742,000) | $(601,000) |
| Long-Term Debt (Less Current Portion) | $3,150,000 | Not explicitly stated for prior period |
| Lines of Credit Outstanding | $1,101,000 | $0 |
Margins: Gross margin decreased to 31.7% from 45.6% year-over-year. The effective tax rate was 34.5% compared to 40.0% in the prior year.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 3.3% to $4.4 million. Product revenue dropped significantly to $1.7 million (from $2.3 million) due to lower sales in microdialysis, electrochemistry, and liquid chromatography. Conversely, services revenue increased to $2.8 million (from $2.3 million) driven by the addition of preclinical services.
- Profitability Deterioration: The Company shifted from a slight operating profit of $18,000 to an operating loss of $472,000. This was primarily driven by a 21.4% increase in total cost of revenue to $3.0 million, largely due to staffing costs associated with the new preclinical services unit.
- Expense Management: Selling expenses decreased 20.9% due to reduced distributor commissions, and R&D expenses decreased 6.9% due to reduced grant activity. However, General and Administrative expenses increased 8.4% due to the new services unit.
- Liquidity Impact: Cash and cash equivalents declined from $1.9 million at the end of the prior quarter (Sept 30, 1999) to $597,000. This decrease was driven by capital expenditures and the acquisition of Toxicology Pathology Services, Inc. (TPS).
Guidance, Outlook, Risks, and Unusual Items
- Acquisition: Effective October 1, 1999, the Company acquired TPS for approximately $430,000, financed via lines of credit. The Company also refinanced approximately $750,000 of TPS debt. Results of TPS are included in the current quarter.
- Capital Expenditures: CapEx was $408,000 for the quarter. Management anticipates reduced levels of capital expenditures for the remainder of fiscal 2000 but expects to continue investing in internal growth and strategic acquisitions.
- Liquidity Outlook: Management believes cash from operations and existing lines of credit (totaling $7.5 million in capacity) will be sufficient to fund working capital and capital expenditure requirements.
- Legal Proceedings: CMA Microdialysis Holding A.B. is suing the Company alleging patent infringement regarding microdialysis probes. The Company denies infringement and asserts the patent is invalid. Sales of the affected product represent less than 1% of revenue. Management believes the outcome will not have a material adverse effect, though legal expenses will continue to impact earnings.
- Debt Covenants: The working capital line of credit requires the maintenance of certain financial ratios.
Investor Verification Checklist
- Verify the sustainability of the new preclinical services revenue stream and its impact on gross margins, which rose to 87.2% of services revenue.
- Monitor the Company's ability to maintain financial ratios required by its $3.5 million working capital line of credit, which expires April 1, 2000.
- Assess the progress and potential cost of the patent infringement litigation with CMA Microdialysis Holding A.B.
- Review the integration of the TPS acquisition and the performance of the contingent incentive payments to former TPS shareholders.
- Track the trend in product revenue, which declined significantly year-over-year, to determine if this is a temporary market fluctuation or a structural shift.